Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote
Company Announcements

Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote

An update from Merrimack Pharmaceuticals Inc. (MACK) is now available.

Merrimack Pharmaceuticals, Inc. has announced a significant milestone with a $225 million payment from Ipsen, S.A. after receiving FDA approval to market ONIVYDE for pancreatic cancer. In light of this, a Special Meeting is scheduled for May 10, 2024, for stockholders to vote on the company’s dissolution and a proposed liquidating dividend, expected to be between $14.68 and $15.30 per share. Merrimack is also establishing a liquidating trust for stockholders to handle any future payments stemming from its agreements with Ipsen and Elevation Oncology, although further milestone payments are considered unlikely.

For a thorough assessment of MACK stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskMerrimack Pharmaceuticals Approves Liquidation and Dividend
TipRanks Auto-Generated NewsdeskMerrimack Pharmaceuticals Plans Liquidating Dividend
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App